Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Long-term Extension Study to Assess the Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis

NCT03835481 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03835481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03835481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Long-term Extension Study to Assess the Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Terminated
Start date
March 18, 2019
Completion date
July 27, 2021
Enrollment
165 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis